Skip to search formSkip to main contentSkip to account menu

Pramipexole

Known as: (S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, 4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine, Pramipexol 
National Institutes of Health

Related topics

Related topics

17 relations
24 HR Pramipexole dihydrochloride 0.75 MG Extended Release Oral TabletDepressive disorderDrug AllergyParkinson Disease

Broader (4)

AntioxidantsAntiparkinson AgentsBenzothiazolesDopamine Agonists

Narrower (6)

KNS 760704MirapexPramipexole dihydrochloride 0.25 MG Oral TabletSND 919CL2x

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep.
Highly Cited
2008
Highly Cited
2008
Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
STUDY OBJECTIVES REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD) which is characterized by… 
Highly Cited
2006
Highly Cited
2006
ISCHEMIC STROKE IN AN ADOLESCENT WITH ARTERIAL TORTUOSITY SYNDROME
I read with interest the article by Oishi et al.1 They report a patient with a right frontal tumor who was strongly right handed… 
Review
2006
Review
2006
Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
Highly Cited
2005
Highly Cited
2005
Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
SummaryThe direct-acting dopamine (DA) agonist pramipexole (2 amino-4,5,6,7-tetrahydro-6-propyl-amino-benzthiazole… 
Highly Cited
2005
Highly Cited
2005
Pramipexole protects against H2O2-induced PC12 cell death
Pramipexole, a novel non-ergot dopamine (DA) agonist, has been successfully applied to the treatment of Parkinson’s disease (PD… 
Highly Cited
2004
Highly Cited
2004
The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors
AbstractRationaleRecent studies have reported antidepressant-like activities of the dopamine D2/D3 agonist pramipexole in the… 
Review
2001
Review
2001
Neuroprotective effects of D3 dopamine receptor agonists.
Highly Cited
2000
Highly Cited
2000
The use of dopamine agonists in very elderly patients with Parkinson's disease
Controversy exists regarding the use of dopamine receptor agonists in elderly patients with Parkinson's disease because of… 
Highly Cited
1995
Highly Cited
1995
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)